All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-12-23T13:36:25.000Z

CellProtect receives EU orphan drug status for the treatment of MM

Dec 23, 2017
Share:

Bookmark this article

The European Medicines Agency (EMA) has granted CellProtect orphan drug designation for the treatment of Multiple Myeloma (MM). CellProtect technology is owned by CellProtect Nordic Pharmaceuticals AB (CPNP), and is, in essence, a process by which a patient's own natural killer (NK) cells are removed, activated, and expanded in-vitro. The activated cells, with enhanced immunocompetence, are then transferred back into the patient, enabling more effective killing of tumor cells.

This therapy is being tested in phase I/II clinical trials with MM patients that are being carried out at the Karolinska University Hospital in Sweden, as a supplementary treatment to Autologous Stem Cell Transplant (ASCT). To date, initial results from these trials have been promising, showing a good safety profile and effective outcomes, with the full results due to be published in 2018. This will be welcome news for MM patients who will be hoping to see effective cell therapies move closer to the clinic.

More about...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox